AN2 THERAPEUTICS INC (ANTX)
US0373261058 - Common Stock
Taking everything into account, ANTX scores 3 out of 10 in our fundamental rating. ANTX was compared to 198 industry peers in the Pharmaceuticals industry. While ANTX has a great health rating, there are worries on its profitability. ANTX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year ANTX has reported negative net income.
In the past year ANTX has reported a negative cash flow from operations.
In the past 5 years ANTX always reported negative net income.
In the past 5 years ANTX always reported negative operating cash flow.
1.2 Ratios
ANTX has a Return On Assets of -46.65%. This is comparable to the rest of the industry: ANTX outperforms 44.10% of its industry peers.
ANTX has a Return On Equity of -51.91%. This is comparable to the rest of the industry: ANTX outperforms 56.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.65% | ||
| ROE | -51.91% | ||
| ROIC | N/A |
ROA(3y)-43.77%
ROA(5y)-115.8%
ROE(3y)-47.36%
ROE(5y)-156.43%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ANTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ANTX has more shares outstanding than it did 1 year ago.
ANTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ANTX has an Altman-Z score of 0.85. This is a bad value and indicates that ANTX is not financially healthy and even has some risk of bankruptcy.
ANTX has a Altman-Z score (0.85) which is comparable to the rest of the industry.
ANTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.85 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 7.87 indicates that ANTX has no problem at all paying its short term obligations.
ANTX's Current ratio of 7.87 is fine compared to the rest of the industry. ANTX outperforms 80.00% of its industry peers.
A Quick Ratio of 7.87 indicates that ANTX has no problem at all paying its short term obligations.
ANTX has a Quick ratio of 7.87. This is amongst the best in the industry. ANTX outperforms 80.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.87 | ||
| Quick Ratio | 7.87 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 40.13% over the past year.
EPS 1Y (TTM)40.13%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q6.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
ANTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 56.21% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y7.19%
EPS Next 2Y5.44%
EPS Next 3Y19.09%
EPS Next 5Y56.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ANTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ANTX's earnings are expected to grow with 19.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.44%
EPS Next 3Y19.09%
5. Dividend
5.1 Amount
ANTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AN2 THERAPEUTICS INC
NASDAQ:ANTX (5/3/2024, 7:00:00 PM)
After market: 2.56 0 (0%)2.56
+0.02 (+0.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap76.36M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.65% | ||
| ROE | -51.91% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.87 | ||
| Quick Ratio | 7.87 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)40.13%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y7.19%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y